




RealRate

PHARMACEUTICAL 2022

Rein Therapeutics Inc
Rank 156 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Rein Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Rein Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 94% points. The greatest weakness of Rein Therapeutics Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 26% points.

The company's Economic Capital Ratio, given in the ranking table, is 344%, being 68% points above the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	48,177
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,508
Liabilities, Non-Current	69
Other Assets	176
Other Compr. Net Income	-11
Other Expenses	0
Other Liabilities	0
Other Net Income	441
Other Revenues	0
Property and Equipment	128
Research and Development	17,008
Selling, General and Administrative Expense	9,597

Output Variable	Value in 1000 USD
Assets	48,481
Liabilities	4,577
Expenses	26,605
Revenues	0
Stockholders Equity	43,904
Net Income	-26,164
Comprehensive Net Income	-26,170
BaseVar	40,058
ECR before LimitedLiability	262%
Economic Capital Ratio	344%